Hypokalemia w/ amphotericin B inj & K-depleting agents. Antagonism w/ anticholinesterases; antihypertensives & diuretics. May potentiate or decrease action of anticoagulants. May increase blood glucose. Enhanced hypokalaemic effects of diuretics including acetazolamide. Increased toxicity of cyclosporine. May enhance digitalis toxicity. May increase t½
& conc & decrease clearance w/ estrogens including OCs. May increase metabolic clearance w/ hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin). May inhibit growth-promoting effect of human growth hormone (eg, somatrem). Increased adverse effects w/ strong CYP3A4 inhibitors (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin. May decrease or enhance neuromuscular blocking action of nondepolarising muscle relaxants. May increase incidence &/or severity of GI bleeding & ulceration w/ NSAIDs. May reduce serum salicylate levels. Decreased metabolic clearance w/ thyroid drugs. Neurological complications & lack of antibody response w/ vaccines.